Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall

MT Newswires Live

Jan 10, 2025

Dyne Therapeutics (DYN) said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE-101 in people with myotonic dystrophy type 1 demonstrated a compelling impact on key disease biomarkers.

This included the knockdown of dystrophin myotonic protein kinase, or DMPK, and splicing correction at the 6.8 mg/kg Q8W dose.

The data also showed a reversal of disease progression across multiple functional endpoints. Improvements were observed in myotonia as measured by video hand opening time, muscle strength through quantitative myometry testing, and dynamic balance.

Dyne said that splicing correction at 3 months supports the use of the composite alternative splicing index as a surrogate endpoint for potential US Accelerated Approval. The data also highlighted a favorable safety profile from 56 patients in the 6.8 mg/kg Q8W cohort.

The company said it plans to initiate a global registrational expansion cohort to support a submission for US accelerated approval based on biomarker and functional data in H1 2026.

Shares of Dyne Therapeutics were down nearly 24% in recent trading.

Price: 17.56, Change: -5.49, Percent Change: -23.82

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502895143"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502895143\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502895143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 23:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502895143","market":"nz","top_or_hot":-1,"title":"Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DYN) said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE-101 in people with myotonic dystrophy type 1 demonstrated a compelling impact on key disease biomarkers.</p><p>This included the knockdown of dystrophin myotonic protein kinase, or DMPK, and splicing correction at the 6.8 mg/kg Q8W dose.</p><p>The data also showed a reversal of disease progression across multiple functional endpoints. Improvements were observed in myotonia as measured by video hand opening time, muscle strength through quantitative myometry testing, and dynamic balance.</p><p>Dyne said that splicing correction at 3 months supports the use of the composite alternative splicing index as a surrogate endpoint for potential US Accelerated Approval. The data also highlighted a favorable safety profile from 56 patients in the 6.8 mg/kg Q8W cohort.</p><p>The company said it plans to initiate a global registrational expansion cohort to support a submission for US accelerated approval based on biomarker and functional data in H1 2026.</p><p>Shares of Dyne Therapeutics were down nearly 24% in recent trading.</p><p>Price: 17.56, Change: -5.49, Percent Change: -23.82</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-10 23:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DYN) said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE-101 in people with myotonic dystrophy type 1 demonstrated a compelling impact on key disease biomarkers.</p><p>This included the knockdown of dystrophin myotonic protein kinase, or DMPK, and splicing correction at the 6.8 mg/kg Q8W dose.</p><p>The data also showed a reversal of disease progression across multiple functional endpoints. Improvements were observed in myotonia as measured by video hand opening time, muscle strength through quantitative myometry testing, and dynamic balance.</p><p>Dyne said that splicing correction at 3 months supports the use of the composite alternative splicing index as a surrogate endpoint for potential US Accelerated Approval. The data also highlighted a favorable safety profile from 56 patients in the 6.8 mg/kg Q8W cohort.</p><p>The company said it plans to initiate a global registrational expansion cohort to support a submission for US accelerated approval based on biomarker and functional data in H1 2026.</p><p>Shares of Dyne Therapeutics were down nearly 24% in recent trading.</p><p>Price: 17.56, Change: -5.49, Percent Change: -23.82</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502895143","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502895143","pubTimestamp":1736524167,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dyne Therapeutics  said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE-101 in people with myotonic dystrophy type 1 demonstrated a compelling impact on key disease biomarkers.This included the knockdown of dystrophin myotonic protein kinase, or DMPK, and splicing correction at the 6.8 mg/kg Q8W dose.The data also showed a reversal of disease progression across multiple functional endpoints. Improvements were observed in myotonia as measured by video hand opening time, muscle strength through quantitative myometry testing, and dynamic balance.Dyne said that splicing correction at 3 months supports the use of the composite alternative splicing index as a surrogate endpoint for potential US Accelerated Approval. The data also highlighted a favorable safety profile from 56 patients in the 6.8 mg/kg Q8W cohort.The company said it plans to initiate a global registrational expansion cohort to support a submission for US accelerated approval based on biomarker and funct","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DYN":"戴纳基","LENZ":"Therapeutics","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓"},"translate_title":"Dyne Therapeutics的肌营养不良症治疗显示DMPK减少、剪接纠正；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"DYN":1},"content_text":"Dyne Therapeutics (DYN) said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE-101 in people with myotonic dystrophy type 1 demonstrated a compelling impact on key disease biomarkers.This included the knockdown of dystrophin myotonic protein kinase, or DMPK, and splicing correction at the 6.8 mg/kg Q8W dose.The data also showed a reversal of disease progression across multiple functional endpoints. Improvements were observed in myotonia as measured by video hand opening time, muscle strength through quantitative myometry testing, and dynamic balance.Dyne said that splicing correction at 3 months supports the use of the composite alternative splicing index as a surrogate endpoint for potential US Accelerated Approval. The data also highlighted a favorable safety profile from 56 patients in the 6.8 mg/kg Q8W cohort.The company said it plans to initiate a global registrational expansion cohort to support a submission for US accelerated approval based on biomarker and functional data in H1 2026.Shares of Dyne Therapeutics were down nearly 24% in recent trading.Price: 17.56, Change: -5.49, Percent Change: -23.82","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}